Drugdocs | Lumoxiti®

Drug updated on 3/28/2024

Dosage Form	Injection (intravenous; 1 mg)
Drug Class	CD22-directed cytotoxins
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Moxetumomab pasudotox-tdfk (Lumoxiti) is used for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including a purine nucleoside analog.
Two systematic reviews/meta-analyses were reviewed to gather information about Lumoxiti's effectiveness and safety in treating HCL.
In one phase 3 trial, moxetumomab pasudotox-tdfk showed an overall response rate of 75% with complete remission observed in 41% of cases among patients with multiple relapses.
The second studysuggests that moxetumomab pasudotox-tdfk can achieve minimal residual disease-free complete remission without chemotherapy toxicities and should be considered before resorting to splenectomy or when adenopathy develops.
Compared to other drugs such as Vemurafenib, Bendamustine/Rituximab, Ibrutinib which also show efficacy against HCL; Lumoxiti has been highlighted for its good tolerance profile among patients according to both documents reviewed.
However, it was noted that high-risk diseases like Hairy Cell Leukemia variant and IGHV4-34+ unmutated HCL require further investigation regarding the use of this drug as per findings from the second document review on Lumoxiti's application in these subgroups.

Document Title	Year	Source
Lumoxiti (moxetumomab pasudotox-tdfk) Prescribing Information.	2022	AstraZeneca Pharmaceuticals LP, Wilmington, DE

Document Title	Year	Source
Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.	2021	Clinical Lymphoma, Myeloma & Leukemia
Treatment of hairy cell leukemia.	2020	Expert Review of Hematology